IGALMI: Sublingual Dexmedetomidine for the Acute Treatment of Agitation in Schizophrenia and Bipolar Disorder

Time: 11:45 am
day: Day One


  • Use of AI for identifying and developing a therapeutic for an underserved indication
  • Overview and key decisions/data in the discovery, formulation and development of IGALMI for treating acute agitation
  • Applying a “Land and Expand” strategy for new indications and broadening commercial opportunities for IGALMI